May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its ...

FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...

Hepatitis B testing can show whether you have a current or past HBV infection and whether you have antibodies from a hepatitis B vaccine. Hepatitis B is a viral infection caused by the hepatitis B ...

GSK plc GSK on Monday entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its ...

HBV infection at birth or during early infancy can lead to lifelong health problems such as chronic liver disease and liver cancer. Newborns are at highest risk, with 90% of those infected with HBV ...

The agreement with Sino Bio, via its subsidiary Chia Tai Tianqing Pharma (CTTQ), allies GSK with a company that is one of ...

Hepatitis B immunoglobulin (HBIG) injections can provide short-term protection against the hepatitis B virus. They may benefit people who have experienced recent exposure. Some people get acute ...

US model study suggests a targeted hepatitis B birth-dose strategy could increase neonatal infections unless screening and ...

Hepatitis B is a viral infection that impacts the liver. To test for hepatitis B, a doctor can perform a blood test that detects hepatitis B surface antigens. A positive result indicates a hepatitis B ...

Researchers found that the decision to delay the once-universal hepatitis B shot for babies will likely cause a surge in ...

Health officials say injection drug use is the highest risk factor for Hepatitis B and C. New cases of hepatitis B and C have risen significantly in North Carolina in recent years. In response, state ...